Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

• How Parkinson’s affects million – and why current treatments are not enough
• Continuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s care
• Serina’s drug candidate SER-252 is designed to deliver continuous symptom relief
• Join Serina CEO Steve Ledger for this live event hosted by FORCE Family Office

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

In this presentation, Mr. Ledger will discuss how advanced Parkinson’s disease impacts millions of people worldwide by affecting their ability to move and maintain quality of life. He will highlight the limitations of current medications, which often wear off quickly or cause unwanted side effects like tremors or stiffness. SER-252 is Serina’s propriety polymer conjugate of apomorphine, a clinically proven dopamine agonist, which is designed to deliver continuous dopaminergic stimulation (CDS), which aims to provide smoother, longer-lasting symptom control and greater convenience. The discussion will also explore the unique advantages of Serina’s POZ Platform, a next-generation drug optimization system with the potential to improve the safety, duration, and tolerability of Parkinson’s treatments and other therapeutics.

The webinar will be hosted by FORCE Family Office CEO, Steve Saltzstein, and include a Q&A session. Attendees may submit questions via the online chat feature during the event.

To register for the complimentary event, please visit:
https://forcefamilyoffice.com/events/healthcare/serina-therapeutics-co ...

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.